Amneal completes acquisition of Kashiv Specialty Pharma

Amneal Pharmaceuticals Inc., based in Bridgewater, has completed its previously announced acquisition of almost all of Kashiv Specialty Pharmaceuticals LLC, it announced Monday.

Amneal, through subsidiary Amneal Pharmaceuticals LLC, acquired a 98% interest in the unit of Kashiv BioSciences LLC for approximately $100 million.

“We are very pleased to announce the completion of this transaction,” Chirag and Chintu Patel, co-CEOs of Amneal, said in a prepared statement. “Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics. Perhaps most importantly, we are adding a team of world-class R&D scientists with a proven track record of developing complex generic products, as well as a platform of innovative drug delivery technologies.”

The deal was first announced in January.